Zytiga launched for advanced prostate cancer

Zytiga (abiraterone) is indicated for use in combination with prednisolone to treat metastatic castration-resistant prostate cancer that has progressed during or after docetaxel treatment.

Zytiga is taken once daily
Zytiga is taken once daily

PHARMACOLOGY

By inhibiting CYP17 (17alpha-hydroxylase/C17,20-lyase), abiraterone blocks the synthesis of testosterone in the adrenal glands and testes, as well as in the prostate tumour itself.1

CLINICAL STUDIES

Approval of abiraterone was based on a randomised, double-blind phase 3 trial in 1195 men with metastatic prostate cancer who had previously received docetaxel. In this trial, men who were given abiraterone 1g daily, plus low-dose prednisone or prednisolone, lived for a median of 14.8 months compared with 10.9 months for men taking placebo plus prednisolone or prednisone.1 This difference translated into a 35.4% reduction in the risk of death with abiraterone compared with placebo (95% CI 23–46%; p<0.001).2

The proportion of patients who experienced a 30% reduction in the worst pain intensity was also significantly greater with abiraterone than placebo (44% vs 27%; p=0.0002).

View Zytiga drug record

Further information: Janssen-Cilag

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Compare COVID-19 vaccines with new MIMS table

Compare COVID-19 vaccines with new MIMS table

Key characteristics of available COVID-19 vaccines...

Deleted products - live tracker

Deleted products - live tracker

EXCLUSIVE TO SUBSCRIBERS See the latest products removed...

Drug price changes - live tracker

Drug price changes - live tracker

EXCLUSIVE TO SUBSCRIBERS Use our constantly updated...

Drug shortages - live tracker

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...